SPRY — ARS Pharmaceuticals, Inc.

Summary of ARS Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $84.3 million for the full year 2025, comprising:
  • U.S. Net Product Revenue: $72.2 million
  • Collaboration Agreements Revenue: $9.7 million
  • Supply Revenue: $2.4 million
• R&D Expenses: $13.2 million, primarily for product development and clinical trials.
• SG&A Expenses: $230.1 million, reflecting significant investment in commercialization efforts.
• Gross to Net Ratio: Low to mid-50% range, targeting around 50% at steady state.
• Cash Position: $245 million in cash, cash equivalents, and short-term investments.

2. Strategic Updates and Business Highlights

• Product Launch: Neffy, the first FDA-approved needle-free treatment for anaphylaxis, had a successful first full year with strong physician engagement.
• Market Dynamics: The company is navigating a refill-driven market where approximately 50% of prescriptions are refills, which complicates new product adoption.
• Sales Force Expansion: Plans to increase the sales force from 106 to 150 representatives, funded through reallocating existing resources without increasing overall SG&A expenses.
• Digital Strategy: Enhanced virtual and digital initiatives, including the "Get neffy on Us" program, which facilitates prescriptions for eligible patients without prior office visits.
• International Expansion: Ongoing regulatory approvals for neffy in Europe, China, Japan, and Australia.

3. Forward Guidance and Outlook

• 2026 Focus: Emphasis on access, adoption, and advancement of neffy, with expectations for improved prescription growth as the installed patient base matures.
• Refill Dynamics: Anticipated increase in refill prescriptions starting in late 2026 as initial prescriptions expire.
• Direct-to-Consumer (DTC) Spending: Expected to remain consistent with 2025 levels, around $100 million, aimed at increasing brand awareness and patient engagement.

4. Bad News, Challenges, or Points of Concern

• Market Structure Challenges: The company faces difficulties due to the established dominance of legacy auto-injectors, which complicates the transition to neffy.
• Prior Authorization Issues: Approximately 55% approval rate for prior authorizations can dampen prescribing momentum.
• Non-linear Growth: Revenue growth has not followed a linear trajectory, reflecting the complexities of market dynamics rather than a lack of demand.

5. Notable Q&A Insights

• Inventory Management: The company is closely monitoring inventory dynamics, particularly as they approach the back-to-school season.
• DTC Campaign Effectiveness: The DTC campaign has increased brand awareness significantly, with aided awareness rising from 20% to 60%.
• Refill Projections: Initial refill activity is expected to emerge in 2026, with a more significant impact anticipated as prescriptions reach expiration.
• Sales Force Funding: Funding for the sales force expansion will come from cuts in market research and advertising budgets, with no overall increase in spending.

Overall, ARS Pharmaceuticals is positioned for growth with strategic adjustments in place to enhance market penetration and operational efficiency, despite facing challenges inherent in transitioning to a new product in a mature market.